Pfizer Animal Health Technical Bulletin

Total Page:16

File Type:pdf, Size:1020Kb

Pfizer Animal Health Technical Bulletin Pfizer Animal Health Technical Bulletin December 2011 Value of CERENIA® (maropitant citrate) in the Treatment of Acute Vomiting in Dogs Matthew Krecic, DVM, MS, MBA, Robert Lavan, DVM, MS, MPVM, Diplomate ACVIM Diplomate ACVPM KEY POINTS • Vomiting is a complex physiological process that is regulated by several brainstem nuclei that comprise the emetic center and chemoreceptor trigger zone (CRTZ) in the central nervous system (CNS). There are multiple causes of vomiting that act via central direct (higher brain), peripheral direct (GI tract), or peripheral indirect (blood borne toxins such as in kidney failure) pathways. Some serious diseases can stimulate the vomiting reflex through both peripheral pathways. Causes of vomiting include diseases of the gastrointestinal (GI) tract, non-GI tract diseases, exposure to toxins, and motion sickness. • CERENIA (maropitant citrate) is an FDA-approved drug for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs 16 weeks and older. Maropitant is a neurokinin receptor (NK1) antagonist that blocks the binding of the endogenous ligand substance P in the CNS. Substance P is the main CNS neurotransmitter that mediates emesis. Because of its pharmacodynamic action at the central NK1 receptor, CERENIA is broadly effective against vomiting caused by central and peripheral signals. • CERENIA (maropitant citrate) Tablets are indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs. CERENIA Injectable Solution is indicated for the prevention and treatment of acute vomiting in dogs. CERENIA is available as an oral tablet (multiple strengths) and as a solution for subcutaneous (SC) injection. The recommended dosing schedules for CERENIA Tablets are 2 mg/kg body weight once daily for up to five consecutive days for the prevention of acute vomiting, and 8 mg/ kg body weight once daily for up to two consecutive days for prevention of vomiting due to motion sickness. The recommended dosing schedule for CERENIA Injectable Solution is 1 mg/kg body weight once daily subcutaneous for up to five consecutive days for the prevention and treatment of acute vomiting. • A retrospective analysis of the US pivotal efficacy study showed that CERENIA added to supportive care was effective in stopping vomiting in dogs with the specific diagnoses of vomiting due to parvovirus, pancreatitis, and gastroenteritis.1 All brands are the property of Pfizer Inc, its affiliates, and/or its licensors. © 2011 Pfizer Inc. All rights reserved. • The dual routes of administration of CERENIA create an opportunity for the veterinarian to continue antiemetic therapy with an oral option (CERENIA Tablets) and/or to allow the pet owner to treat the pet at home. • The once daily administration of CERENIA may be less stressful for the pet and pet owner compared to other medications that must be dosed multiple times a day. • In a recent Veterinary Online Interactive Community Exchange (VOICE) Pfizer market research survey, 86.5% (n=122/147) of responding veterinarians identified CERENIA as the antiemetic treatment that they were most confident would stop vomiting in dogs.2 • In the same survey, 92% (n=132/143) of responding veterinarians indicated that adding an antiemetic to supportive care shortens recovery time for a vomiting dog, and 99% (n=140/141) of respondents indicated that a medication that shortens the duration of hospitalization and speeds recovery was valuable to their practice.2 • In the same survey, 84% (n=119/141) of responding veterinarians noted that rapid resolution of emesis has a beneficial effect on a dog’s quality of life, and that of the dog owner.2 INTRODUCTION substance P to NK1 receptors. NK1 receptors are Vomiting equals suffering. Identifying and densely distributed within the emetic center and countering a specific cause of vomiting is of maropitant acts to directly inhibit vomiting by primary importance, yet stopping the vomiting blocking substance P binding at these NK1 receptors is also important to address the patient’s in the CNS. immediate physical needs while investigating or The predominant peripheral direct and indirect treating for the specific cause. pathways carry stimuli to induce vomiting through the emetic center and CRTZ, respectively. All Vomiting is a nonspecific clinical sign; it is similar stimuli that cause vomiting converge within the to other vague clinical signs such as lethargy and emetic center; therefore, stimuli, such as toxins depression. Common GI diseases include foreign retained by diseased kidneys, within the circulation bodies, gastroenteritis, inflammatory bowel disease, initially carried to the CRTZ via the peripheral neoplasia (eg, lymphosarcoma), parasitism, and indirect pathway ultimately end within the emetic canine parvovirus. Common non-GI diseases include center. Alternatively, the peripheral direct pathway hypoadrenocorticism, hyperthyroidism, kidney carries stimuli from diseased abdominal organs right disease (uremia), liver disease, and pancreatitis. to the emetic center. The emetic center also directly Additionally, toxins (eg, lead) and medications (eg, receives stimuli that induce vomiting from the digoxin, chemotherapies) may also cause vomiting. higher brain (ie, cerebrum) via the central pathway. Identifying and countering a specific cause of vomiting The CRTZ likewise also receives stimuli from the is of primary importance, yet stopping the vomiting is vestibular apparatus, which underlies vomiting an important component of addressing the patient’s due to motion sickness. Some diseases can cause immediate physical needs while investigating or vomiting due to multiple pathways. Once the emetic treating for the specific cause. Despite the many causes center and CRTZ receive these stimuli, substance of vomiting, effectively stopping the vomiting while P is released and binds to NK1 receptors within the allowing for further examination is possible with the emetic center and CRTZ. This interaction induces antiemetic CERENIA (maropitant citrate). efferent nerve impulses to the abdominal muscles and diaphragm to start the vomiting reflex. Maropitant is a neurokinin (NK1) receptor antagonist that blocks the binding of the endogenous ligand The injectable form (10 mg/ml) of CERENIA, dosed 2 at 1 mg/kg SC once daily for up to five consecutive CERENIA was the only agent that effectively days, is labeled for prevention and treatment of acute prevented vomiting regardless of the emetic stimuli. vomiting in dogs. The tablet form (16, 24, 60, and 160 mg) of CERENIA is labeled for prevention of acute vomiting and prevention of vomiting due to motion Additionally in laboratory studies, researchers have sickness in dogs. The oral dose for preventing and demonstrated the effectiveness of CERENIA in treating acute vomiting is 2 mg/kg once daily for up to controlling emesis from challenges with two emetics, 5 five consecutive days, and the oral dose for preventing syrup of ipecac and apomorphine. When a dog motion sickness is 8 mg/kg once daily for up to two ingests syrup of ipecac, it irritates the stomach, consecutive days. However, a combination of injectable stimulating vomiting via the peripheral direct pathway. and oral CERENIA not to exceed five consecutive Apomorphine administered intravenously (IV) days may be prescribed to dogs with acute vomiting. travels to the CRTZ where it stimulates dopamine CERENIA does not have any known contraindications. receptors, leading to vomiting; this is via the peripheral indirect pathway. Compared to the antiemetics Since 2007, Cerenia has become the most metoclopramide, chlorpromazine, and ondansetron, prescribed antiemetic, with 74% of all practice CERENIA effectively prevented vomiting regardless of veterinarians prescribing it.3 the emetic stimuli. Researchers showed metoclopramide and chlorpromazine to be effective at preventing vomiting induced by apomorphine but not by syrup of CERENIA became commercially available in the US ipecac. Similarly, researchers showed ondansetron to in 2007. Since then, it has become the most prescribed be effective at preventing vomiting induced by syrup antiemetic, with 74% of all practice veterinarians of ipecac but not by apomorphine. CERENIA was prescribing it.3 Since launch, the recommended length of the only agent that effectively prevented vomiting time the injectable form can be stored once opened has in the vast majority of cases regardless of the emetic been increased. An opened vial of CERENIA now has a stimuli. Since the introduction of CERENIA to the 90-day shelf life, increased from the previously approved marketplace, other CERENIA-related studies have been 28 days. published.6-9 DESCRIPTION OF THE CERENIA US PIVOTAL EFFICACY STUDY A RETROSPECTIVE EXAMINATION OF THE CERENIA US PIVOTAL A summary of the results from the CERENIA US 10 pivotal efficacy study were published in 2008.4 This EFFICACY STUDY study supported the New Animal Drug Application Data from the CERENIA pivotal efficacy study and the approval of CERENIA for use in the treatment was retrospectively examined to determine if the and prevention of acute emesis in dogs. The study performance of CERENIA could be described in was started in August 2003 and the last patient was several subpopulations of dogs sharing common enrolled in June 2004. All dogs had been vomiting at diagnoses that could be driving the vomiting enrollment and all were treated for three to five days. (See Appendix). Approximately 70% (n = 183) of Data were
Recommended publications
  • Deciphering Emesis
    International Journal of Pharmaceutical Chemistry and Analysis 2021;8(1):19–24 Content available at: https://www.ipinnovative.com/open-access-journals International Journal of Pharmaceutical Chemistry and Analysis Journal homepage: https://www.ijpca.org/ Review Article Deciphering emesis 1, 2 Sunil Chaudhry *, Avisek Dutta 1Bioclinitech Technologies Pvt Ltd, Mumbai & GPATTutor.com,, India 2Cognizant Aolutions, Kolkata, West Bengal, India ARTICLEINFO ABSTRACT Article history: The incidence of nausea or vomiting changes much with etiopathogenesis. Multiple neurohumoural Received 04-03-2021 pathways lead to nausea and vomiting. The various classes of antiemetics target different pro-emetic Accepted 09-03-2021 pathways to alleviate nausea and vomiting. Some drugs target more than one pathway. It is demonstrated Available online 04-05-2021 that combination therapy is more effective than single anti-emetic agent. © This is an open access article distributed under the terms of the Creative Commons Attribution Keywords: License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and Vomiting reproduction in any medium, provided the original author and source are credited. Chemoreceptor trigger zone Aprepitant Cannabinoid receptor agonist 5 HT receptor antagonist Neurokinin receptor antagonists 1. Introduction 5. Refractory: Nausea and/or vomiting that occurs in subsequent chemotherapy cycles despite maximum Vomiting or emesis, is defined as the involuntary, forceful antiemetic protocol expulsion of the contents of stomach through the mouth and 6. Anticipatory: Nausea and/or vomiting that is sometimes from nose. triggered by sensory stimuli associated with chemotherapy administration. 1 2. Types of Vomiting Features of Cancer Chemotherapy induced nausea and 2.1. Vomiting centre vomiting: The chemoreceptor trigger zone in the Area postrema plays 1.
    [Show full text]
  • Treatment Recommendations for Feline Pancreatitis
    Treatment recommendations for feline pancreatitis Background is recommended. Fentanyl transdermal patches have become Pancreatitis is an elusive disease in cats and consequently has popular for pain relief because they provide a longer duration of been underdiagnosed. This is owing to several factors. Cats with analgesia. It takes at least 6 hours to achieve adequate fentanyl pancreatitis present with vague signs of illness, including lethargy, levels for pain control; therefore, one recommended protocol is to decreased appetite, dehydration, and weight loss. Physical administer another analgesic, such as intravenous buprenorphine, examination and routine laboratory findings are nonspecific, and at the time the fentanyl patch is placed. The cat is then monitored until recently, there have been limited diagnostic tools available closely to see if additional pain medication is required. Cats with to the practitioner for noninvasively diagnosing pancreatitis. As a chronic pancreatitis may also benefit from pain management, and consequence of the difficulty in diagnosing the disease, therapy options for outpatient treatment include a fentanyl patch, sublingual options are not well understood. buprenorphine, oral butorphanol, or tramadol. Now available, the SNAP® fPL™ and Spec fPL® tests can help rule Antiemetic therapy in or rule out pancreatitis in cats presenting with nonspecific signs Vomiting, a hallmark of pancreatitis in dogs, may be absent or of illness. As our understanding of this disease improves, new intermittent in cats. When present, vomiting should be controlled; specific treatment modalities may emerge. For now, the focus is and if absent, treatment with an antiemetic should still be on managing cats with this disease, and we now have the tools considered to treat nausea.
    [Show full text]
  • The Effect of Intravenous Maropitant on Blood Pressure in Healthy Awake and Anesthetized Dogs
    Veterinary Clinical Sciences Publications Veterinary Clinical Sciences 2-27-2020 The effect of intravenous maropitant on blood pressure in healthy awake and anesthetized dogs Ting-Ting Chi Iowa State University, [email protected] Bonnie L. Hay Kraus Iowa State University, [email protected] Follow this and additional works at: https://lib.dr.iastate.edu/vcs_pubs Part of the Comparative and Laboratory Animal Medicine Commons, and the Small or Companion Animal Medicine Commons The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/ vcs_pubs/39. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Veterinary Clinical Sciences at Iowa State University Digital Repository. It has been accepted for inclusion in Veterinary Clinical Sciences Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. The effect of intravenous maropitant on blood pressure in healthy awake and anesthetized dogs Abstract Objective To evaluate the effects of intravenous maropitant on arterial blood pressure in healthy dogs while awake and under general anesthesia. Design Experimental crossover study. Animals Eight healthy adult Beagle dogs. Procedure All dogs received maropitant (1 mg kg-1) intravenously under the following conditions: 1) awake with non-invasive blood pressure monitoring (AwNIBP), 2) awake with invasive blood pressure monitoring (AwIBP), 3) premedication with acepromazine (0.005 mg kg-1) and butorphanol (0.2 mg kg-1) intramuscularly followed by propofol induction and isoflurane anesthesia (GaAB), and 4) premedication with dexmedetomidine (0.005 mg kg-1) and butorphanol (0.2 mg kg-1) intramuscularly followed by propofol induction and isoflurane anesthesia (GaDB).
    [Show full text]
  • The Vomiting Center and the Chemoreceptor Trigger Zone
    Pharmacologic Control of Vomiting Todd R. Tams, DVM, Dipl. ACVIM VCA West Los Angeles Animal Hospital Pharmacologic Control of Acute Vomiting Initial nonspecific management of vomiting includes NPO (in minor cases a 6-12 hour period of nothing per os may be all that is required), fluid support, and antiemetics. Initial feeding includes small portions of a low fat, single source protein diet starting 6-12 hours after vomiting has ceased. Drugs used to control vomiting will be discussed here. The most effective antiemetics are those that act at both the vomiting center and the chemoreceptor trigger zone. Vomiting is a protective reflex and when it occurs only occasionally treatment is not generally required. However, patients that continue to vomit should be given antiemetics to help reduce fluid loss, pain and discomfort. For many years I strongly favored chlorpromazine (Thorazine), a phenothiazine drug, as the first choice for pharmacologic control of vomiting in most cases. The HT-3 receptor antagonists ondansetron (Zofran) and dolasetron (Anzemet) have also been highly effective antiemetic drugs for a variety of causes of vomiting. Metoclopramide (Reglan) is a reasonably good central antiemetic drug for dogs but not for cats. Maropitant (Cerenia) is a superior broad spectrum antiemetic drug and is now recognized as an excellent first choice for control of vomiting in dogs. Studies and clinical experience have now also shown maropitant to be an effective and safe antiemetic drug for cats. While it is labeled only for dogs, clinical experience has shown it is safe to use the drug in cats as well. Maropitant is also the first choice for prevention of motion sickness vomiting in both dogs and cats.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • Efficacy of Maropitant in Preventing Vomiting in Dogs Premedicated with Hydromorphone Bonnie L
    Veterinary Clinical Sciences Publications Veterinary Clinical Sciences 1-2013 Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone Bonnie L. Hay Kraus Iowa State University, [email protected] Follow this and additional works at: https://lib.dr.iastate.edu/vcs_pubs Part of the Small or Companion Animal Medicine Commons, and the Veterinary Toxicology and Pharmacology Commons The ompc lete bibliographic information for this item can be found at https://lib.dr.iastate.edu/ vcs_pubs/29. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Veterinary Clinical Sciences at Iowa State University Digital Repository. It has been accepted for inclusion in Veterinary Clinical Sciences Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone Abstract Objective The og al of this study was to evaluate the effectiveness of maropitant (Cerenia®) in preventing vomiting after premedication with hydromorphone. Study design Randomized, blinded, prospective clinical study. Animals Eighteen dogs ASA I/II admitted for elective orthopedic surgical procedures. The dogs were a mixed population of males and females, purebreds and mixed breeds, 1.0–10.2 years of age, weighing 3–49.5 kg. Methods Dogs were admitted to the study if they were greater than 1 year of age, healthy and scheduled to undergo elective orthopedic surgery. Dogs were randomly selected to receive one of two treatments administered by subcutaneous injection.
    [Show full text]
  • Neurokinin Receptor NK Receptor
    Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Aprepitant (MK-0869) is a selective and Befetupitant is a high-affinity, nonpeptide, high-affinity neurokinin 1 receptor antagonist competitive tachykinin 1 receptor (NK1R) with a Kd of 86 pM. antagonist. Purity: 99.67% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg Biotin-Substance P Casopitant mesylate Cat. No.: HY-P2546 (GW679769B) Cat. No.: HY-14405A Biotin-Substance P is the biotin tagged Substance Casopitant mesylate (GW679769B) is a potent, P. Substance P (Neurokinin P) is a neuropeptide, selective, brain permeable and orally active acting as a neurotransmitter and as a neurokinin 1 (NK1) receptor antagonist.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.446,029 B2 Boscan Et Al
    USOO9446O29B2 (12) United States Patent (10) Patent No.: US 9.446,029 B2 BOScan et al. (45) Date of Patent: Sep. 20, 2016 (54) USE OF NK-1 RECEPTOR ANTAGONISTS IN GB 2216529 10, 1989 MANAGEMENT OF VISCERAL PAIN WO 9102745 A1 3, 1991 WO 911226.6 A1 8, 1991 (75) Inventors: Pedro Boscan, Bellvue, CO (US); WO O11801.6 A1 3, 2001 David Twedt, Fort Collins, CO (US) OTHER PUBLICATIONS (73) Assignee: Colorado State University Research Glerum et al. (Veterinary Surgery, 30, 351-358, 2001).* Foundation, Fort Collins, CO (US) Devitt et al. (JAVMA, 227, 6, Sep. 15, 2005).* Papich (Veterinary Pharmacology and Therapeutics, Ninth Edition, (*) Notice: Subject to any disclaimer, the term of this 2009, p. 1247-1272, editors: Jim E. Riviere Mark G. Papich).* patent is extended or adjusted under 35 Bradesi et al. (Gastroenterology, 2006, 130, 1729-1742).* U.S.C. 154(b) by 452 days. Heard, D.J. et al. Effect of acepromazine on the anesthetic require ment of halothane in the dog, AJVR, 1986, pp. 2113-2115, vol. 47. (21) Appl. No.: 13/192.283 No. 10. Hellyer, P.W. et al. Effects of diazepam and flumazenil on minimum alveolar concentrations for dogs anesthetized with isoflurane or a (22) Filed: Jul. 27, 2011 combination of isoflurane and fentanyl, AJVR, 2001, pp. 555-560, (65) Prior Publication Data vol. 62, No. 4. Muir, W.W. III, et al. Effects of morphine, lidocaine, ketamine, and US 2012/002898O A1 Feb. 2, 2012 morphine-lidocaine-ketamine drug combination on minimum alveolar concentration in dogs anesthetized with isoflurane, AJVR, Related U.S.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Cerenia, INN-Maropitant Citrate
    EMEA/V/C/0106 EMEA/CVMP/254129/2006 EPAR summary for the public Cerenia Maropitant This document is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use. This document cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR). What is Cerenia? Cerenia is a medicine that contains the active substance maropitant. It is available as tablets (16, 24, 60 and 160 mg) for dogs, and as a solution for injection (10 mg/ml) under the skin or into a vein for dogs and cats. What is Cerenia used for? Cerenia is used to treat vomiting in dogs and cats (solution for injection) or to prevent vomiting in dogs (tablets), in combination with other supportive measures. In dogs the tablets can be used to prevent vomiting due to motion sickness. In cats the solution for injection is used to prevent vomiting and to reduce nausea, but is not suitable for motion (travel) sickness. Cerenia solution for injection is used in dogs both to prevent nausea and vomiting before and after an operation and to improve recovery from general anaesthesia after use of morphine. Cerenia is used to prevent (tablets and solution for injection) and treat (solution for injecton) nausea caused by chemotherapy in dogs.
    [Show full text]
  • Maropitant: Novel Antiemetic
    MEDICATIONS > PHARMACOLOGY > PEER REVIEWED Maropitant: Novel Antiemetic Lauren A. Trepanier, DVM, PhD, DACVIM, DACVCP University of Wisconsin–Madison Vomiting can lead to dehydration, weight loss, reflux esophagitis, or aspiration pneumonia. Antiemetics reduce the frequency of vomiting and make patients more comfortable. Vomiting severe enough to warrant an antiemetic should also prompt a reason- able evaluation to look for serious underlying disease, including an abdominal radiograph to assist in ruling out GI obstruction. Antiemetics can reduce the frequency of vomiting and Administration of antiemetics empirically in animals with unrec- make patients more comfortable. Vomiting severe enough ognized GI obstruction can delay diagnosis and potentially to warrant an antiemetic should also prompt a reasonable worsen prognosis. If vomiting is severe or persistent, CBC, chem- evaluation to look for serious underlying disease. istry panel, and a pancreatic lipase test are indicated. Repeated dosing of antiemetics should be avoided unless patients have had this baseline completed. If intestinal obstruction is noted, anti- Chemotherapy emetics without prokinetic properties can be continued while NK-1 antagonists have become the standard of care in human surgery is planned. and veterinary cancer patients to prevent vomiting associated with chemotherapy. This may improve quality of life during Maropitant & Its Actions treatment, prevent expensive hospitalization, and decrease the One of the most effective veterinary antiemetics is maropitant need for chemotherapy dose reductions. Maropitant is effective (cerenia.com). It is the first veterinary neurokinin-1 (NK-1) recep- in preventing cisplatin-associated vomiting in dogs when admin- tor antagonist and inhibits binding of substance P to NK-1 recep- istered 1 hour before SC infusion.6 tors.
    [Show full text]
  • A Few of My Favorite Things for Cat Anesthesia and Analgesia Tamara Grubb, DVM, Phd, DACVAA Washington State University Pullman, WA
    A Few of My Favorite Things for Cat Anesthesia and Analgesia Tamara Grubb, DVM, PhD, DACVAA Washington State University Pullman, WA These are a few of my favorite things. Some you will have, some you won’t, some might surprise you. The list encompasses equipment, drugs and techniques. Equipment and ‘stuff’ Esophageal stethoscope One of the least expensive pieces of equipment you can buy. More accurate for counting heart rate than the ECG monitor (sometimes the monitor doesn’t know which spikes to count on the ECG tracing) and more useful for indicating that the heart is actually beating (because sound = contraction/flow) than the ECG (electrical activity can occur without any cardiac function). • Advantages: EASY, cheap. Can hook up to a speaker so everyone in the room can help monitor the patient. • Disadvantages: MIGHT cause reflux esophagitis if inserted into the stomach; patient could bite it off if not removed before the patient wakes up. • Source: Multiple companies Bain ‘block’ or ‘mount Block or mount for attachment of a pressure manometer and scavenging system to the rebreathing system. This allows the pressure generated by a delivered breath to be MEASURED, which decreases likelihood of barotrauma (pressure too high) or inadequate ventilation (pressure too low). Also decreases contamination of room with waste gas because of attachment to scavenging system. • Source: Multiple companies ‘Pop-off’ occlusion valve (or ‘occlusion button’) Instead of completely closing the pop-off (or ‘pressure relief’) valve to give the patient a breath, just push this button for temporary closure of the valve. When you release the pressure on the button, the valve is automatically open.
    [Show full text]